PRVA vs AGIO

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus 22. 3% for Privia Health Group, Inc. (PRVA). Privia Health Group, Inc. (PRVA) offers the better valuation at 133. 3x trailing P/E (68. 5x forward), making it the more compelling value choice. Analysts rate Privia Health Group, Inc. (PRVA) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Privia Health Group, Inc.

(PRVA) delivered a total return of -26. 1%, compared to -50. 7% for Agios Pharmaceuticals, Inc. (AGIO). Over 10 years, the gap is even starker: PRVA returned +4. 3% versus AGIO's -42. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Privia Health Group, Inc.

(PRVA) is the lower-risk stock at 1. 03β versus Agios Pharmaceuticals, Inc. 's 1. 12β — meaning AGIO is approximately 9% more volatile than PRVA relative to the S&P 500. On balance sheet safety, Privia Health Group, Inc. (PRVA) carries a lower debt/equity ratio of 1% versus 5% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus 22. 3% for Privia Health Group, Inc. (PRVA). On earnings-per-share growth, the picture is similar: Privia Health Group, Inc. grew EPS 63. 6% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Privia Health Group, Inc.

(PRVA) is the more profitable company, earning 1. 1% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 1. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRVA leads at 1. 6% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AGIO: 37.

1% to $37. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Privia Health Group, Inc.

(PRVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Both have compounded well over 10 years (PRVA: +4. 3%, AGIO: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.